Junko Hamamoto

1.7k citations

28 papers · 820 · h-index 16

Impact in

Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations
Oncology top 10%
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis

Papers in

Pulmonary and Respiratory Medicine 16
- Lung Cancer Treatments and Mutations 15
Molecular Biology 15
- Cancer therapeutics and mechanisms 5
- PI3K/AKT/mTOR signaling in cancer 4
- Epigenetics and DNA Methylation 3

Co-authors: Hiroyuki Yasuda (25 shared papers)Kenzo Soejima (23 shared papers)Katsuhiko Naoki (17 shared papers)Tomoko Betsuyaku (14 shared papers)Ichiro Kawada (15 shared papers)Shigenari Nukaga (9 shared papers)Daisuke Arai (9 shared papers)Toshiyuki Hirano (6 shared papers)
Journals: Cancer Research (4 papers)Molecular Cancer Research (3 papers)Molecular Cancer Therapeutics (3 papers)International Journal of Oncology (2 papers)Lung Cancer (2 papers)
Partner nations: Japan United States France

In The Last Decade

Junko Hamamoto

26 papers receiving 816 citations

Peers

Countries citing papers authored by Junko Hamamoto

Since Specialization

Citations

This map shows the geographic impact of Junko Hamamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junko Hamamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junko Hamamoto more than expected).

Fields of papers citing papers by Junko Hamamoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junko Hamamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junko Hamamoto. The network helps show where Junko Hamamoto may publish in the future.

Co-authors

The 25 scholars most cited alongside Junko Hamamoto, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Junko Hamamoto Line = papers co-authored together Junko Hamamoto links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors Cancer Research ·Shigenari Nukaga, Hiroyuki Yasuda, Katsuya Tsuchihara, Junko Hamamoto, Keita Masuzawa, Ichiro Kawada, Katsuhiko Naoki, Shingo Matsumoto, Sachiyo Mimaki, Shinnosuke Ikemura, Kōichi Goto, Tomoko Betsuyaku, Kenzo Soejima	2017	135
2	In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer Oncotarget ·Toshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani, Junko Hamamoto, Ayano Oashi, Kota Ishioka, Daisuke Arai, Shigenari Nukaga, Masayoshi Miyawaki, Ichiro Kawada, Katsuhiko Naoki, Daniel B. Costa, Susumu Kobayashi, Tomoko Betsuyaku, Kenzo Soejima	2015	129
3	Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer Molecular Cancer Research ·Masayoshi Miyawaki, Hiroyuki Yasuda, Tetsuo Tani, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Shigenari Nukaga, Toshiyuki Hirano, Ichiro Kawada, Katsuhiko Naoki, Yuichiro Hayashi, Tomoko Betsuyaku, Kenzo Soejima	2016	58
4	Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK -Translocated Lung Cancer Cells Molecular Cancer Therapeutics ·Tetsuo Tani, Hiroyuki Yasuda, Junko Hamamoto, Aoi Kuroda, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Masayoshi Miyawaki, Ichiro Kawada, Katsuhiko Naoki, Yuichiro Hayashi, Tomoko Betsuyaku, Kenzo Soejima	2015	54
5	Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening Cell Reports ·Toshiki Ebisudani, Shinya Sugimoto, Kei Haga, Akifumi Mitsuishi, Reiko Takai‐Todaka, Masayuki Fujii, Kohta Toshimitsu, Junko Hamamoto, Kai Sugihara, Tomoyuki Hishida, Hisao Asamura, Koichi Fukunaga, Hiroyuki Yasuda, Kazuhiko Katayama, Toshiro Sato	2021	43
6	Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations Lung Cancer ·Hanako Hasegawa, Hiroyuki Yasuda, Junko Hamamoto, Keita Masuzawa, Tetsuo Tani, Shigenari Nukaga, Toshiyuki Hirano, Keigo Kobayashi, Tadashi Manabe, Hideki Terai, Shinnosuke Ikemura, Ichiro Kawada, Katsuhiko Naoki, Kenzo Soejima	2018	40
7	IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer Molecular Cancer Research ·Tadashi Manabe, Hiroyuki Yasuda, Hideki Terai, Harumi Kagiwada, Junko Hamamoto, Toshiki Ebisudani, Keigo Kobayashi, Keita Masuzawa, Shinnosuke Ikemura, Ichiro Kawada, Yuichiro Hayashi, Kazuhiko Fukui, Katsuhisa Horimoto, Koichi Fukunaga, Kenzo Soejima	2020	39
8	The PCR-invader method (structure-specific 5′ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing International Journal of Clinical Oncology ·Katsuhiko Naoki, Kenzo Soejima, Hiroaki Okamoto, Junko Hamamoto, Naoya Hida, Ichiro Nakachi, Hiroyuki Yasuda, Sohei Nakayama, Satoshi Yoda, Ryosuke Satomi, Shinnosuke Ikemura, Hideki Terai, Takashi Sato, Koshiro Watanabe	2011	39
9	Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations Oncotarget ·Keita Masuzawa, Hiroyuki Yasuda, Junko Hamamoto, Shigenari Nukaga, Toshiyuki Hirano, Ichiro Kawada, Katsuhiko Naoki, Kenzo Soejima, Tomoko Betsuyaku	2017	39
10	Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR -Mutated Non–Small Cell Lung Cancer Molecular Cancer Therapeutics ·Toshiyuki Hirano, Hiroyuki Yasuda, Junko Hamamoto, Shigenari Nukaga, Keita Masuzawa, Ichiro Kawada, Katsuhiko Naoki, Tatsuya Niimi, Shinya Mimasu, Hideki Sakagami, Kenzo Soejima, Tomoko Betsuyaku	2018	31
11	Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma Journal of Cancer ·Makoto Nishino, Mari Ozaki, Ahmed E. Hegab, Junko Hamamoto, Shizuko Kagawa, Daisuke Arai, Hiroyuki Yasuda, Katsuhiko Naoki, Kenzo Soejima, Hideyuki Saya, Tomoko Betsuyaku	2017	30
12	Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms Lung Cancer ·Ahmed E. Hegab, Mari Ozaki, Shizuko Kagawa, Junko Hamamoto, Hiroyuki Yasuda, Katsuhiko Naoki, Kenzo Soejima, Yongjun Yin, Tomonari Kinoshita, Tomonori Yaguchi, Yutaka Kawakami, David M. Ornitz, Tomoko Betsuyaku	2018	28
13	Characterization of the cell of origin and propagation potential of the fibroblast growth factor 9‐induced mouse model of lung adenocarcinoma The Journal of Pathology ·Daisuke Arai, Ahmed E. Hegab, Kenzo Soejima, Aoi Kuroda, Kota Ishioka, Hiroyuki Yasuda, Katsuhiko Naoki, Shizuko Kagawa, Junko Hamamoto, Yongjun Yin, David M. Ornitz, Tomoko Betsuyaku	2014	22
14	Impacts of the introduction of a triage system in Japan: A time series study International Emergency Nursing ·Junko Hamamoto, Hiroaki Yamase, Yoshie Yamase	2013	22
15	Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy Gynecologic Oncology ·Yuya Yoshimoto, Yasushi Sasaki, Kazutoshi Murata, Shin‐ei Noda, Yuhei Miyasaka, Junko Hamamoto, Mio Furuya, Junko Hirato, Yoshiyuki Suzuki, Tatsuya Ohno, Takashi Tokino, Takahiro Oike, Takashi Nakano	2020	20
16	Multiple roles of extracellular fibroblast growth factors in lung cancer cells International Journal of Oncology ·Takahiro Suzuki, Hiroyuki Yasuda, KOJI FUNAISHI, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Tetsuo Tani, Junko Hamamoto, Ayano Ohashi, Katsuhiko Naoki, Tomoko Betsuyaku, Kenzo Soejima	2014	16
17	Effects of the common polymorphism in the human aldehyde dehydrogenase 2 (ALDH2) gene on the lung Respiratory Research ·Aoi Kuroda, Ahmed E. Hegab, Jingtao Gao, Shuji Yamashita, Nobuyuki Hizawa, Tohru Sakamoto, Hideyasu Yamada, Satoshi Suzuki, Makoto Ishii, Ho Namkoong, Takanori Asakura, Mari Ozaki, Hiroyuki Yasuda, Junko Hamamoto, Shizuko Kagawa, Kenzo Soejima, Tomoko Betsuyaku	2017	15
18	Long-term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR-mutant PC9 lung cancer cell line International Journal of Oncology ·Hideki Terai, Kenzo Soejima, Hiroyuki Yasuda, Takashi Sato, Katsuhiko Naoki, Shinnosuke Ikemura, Daisuke Arai, Keiko Ohgino, Kota Ishioka, Junko Hamamoto, Yae Kanai, Tomoko Betsuyaku	2014	14
19	SHOC2 Is a Critical Modulator of Sensitivity to EGFR–TKIs in Non–Small Cell Lung Cancer Cells Molecular Cancer Research ·Hideki Terai, Junko Hamamoto, Katsura Emoto, Takeshi Masuda, Tadashi Manabe, Satoshi Kuronuma, Keigo Kobayashi, Keita Masuzawa, Shinnosuke Ikemura, Sohei Nakayama, Ichiro Kawada, Yusuke Suzuki, Osamu Takeuchi, Yukio Suzuki, Sumio Ohtsuki, Hiroyuki Yasuda, Kenzo Soejima, Koichi Fukunaga	2020	13
20	Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors Oncology Letters ·Junko Hamamoto, Hiroyuki Yasuda, Kaito Aizawa, Makoto Nishino, Shigenari Nukaga, Toshiyuki Hirano, Ichiro Kawada, Katsuhiko Naoki, Tomoko Betsuyaku, Kenzo Soejima	2017	13

About Junko Hamamoto

Junko Hamamoto is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Organic Chemistry and Cancer Research, having authored 28 papers that have together received 820 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (15 papers), Cancer therapeutics and mechanisms (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Cancer Genomics and Diagnostics (3 papers), Quinazolinone synthesis and applications (3 papers), Lung Cancer Research Studies (3 papers), Epigenetics and DNA Methylation (3 papers) and Cancer Cells and Metastasis (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (506 citations), Oncology (354 citations), Cancer Research (118 citations), Molecular Biology (368 citations) and Pathology and Forensic Medicine (57 citations). Junko Hamamoto has collaborated with scholars based in Japan, United States and France. Frequent co-authors include Hiroyuki Yasuda, Kenzo Soejima, Katsuhiko Naoki, Tomoko Betsuyaku, Ichiro Kawada, Shigenari Nukaga, Daisuke Arai, Toshiyuki Hirano, Keita Masuzawa and Tetsuo Tani. Their work appears in journals such as Cancer Research, Molecular Cancer Research, Molecular Cancer Therapeutics, International Journal of Oncology and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Junko Hamamoto

Impact in

Papers in i

In The Last Decade

Junko Hamamoto

Peers

Countries citing papers authored by Junko Hamamoto

Fields of papers citing papers by Junko Hamamoto

All Works

About Junko Hamamoto

Explore authors with similar magnitude of impact

Papers in